ATE220688T1 - Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen - Google Patents

Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen

Info

Publication number
ATE220688T1
ATE220688T1 AT91903963T AT91903963T ATE220688T1 AT E220688 T1 ATE220688 T1 AT E220688T1 AT 91903963 T AT91903963 T AT 91903963T AT 91903963 T AT91903963 T AT 91903963T AT E220688 T1 ATE220688 T1 AT E220688T1
Authority
AT
Austria
Prior art keywords
enterotoxins
tumor
related compounds
destructive effects
destructive
Prior art date
Application number
AT91903963T
Other languages
English (en)
Inventor
David S Terman
Jay L Stone
Original Assignee
David S Terman
Jay L Stone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23852299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE220688(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by David S Terman, Jay L Stone filed Critical David S Terman
Application granted granted Critical
Publication of ATE220688T1 publication Critical patent/ATE220688T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4534—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91903963T 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen ATE220688T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46657790A 1990-01-17 1990-01-17
PCT/US1991/000342 WO1991010680A1 (en) 1990-01-17 1991-01-17 Tumor killing effects of enterotoxins and related compounds

Publications (1)

Publication Number Publication Date
ATE220688T1 true ATE220688T1 (de) 2002-08-15

Family

ID=23852299

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01104586T ATE304371T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
AT01102715T ATE303157T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie
AT91903963T ATE220688T1 (de) 1990-01-17 1991-01-17 Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT01104586T ATE304371T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
AT01102715T ATE303157T1 (de) 1990-01-17 1991-01-17 Verwendung von staphylococcus-enterotoxinen oder verwandte verbindungen für krebs-therapie

Country Status (5)

Country Link
EP (3) EP1103268B1 (de)
AT (3) ATE304371T1 (de)
CA (1) CA2078003C (de)
DE (3) DE69133484T2 (de)
WO (1) WO1991010680A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903100D0 (sv) † 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US5529934A (en) * 1991-07-29 1996-06-25 Biomide Investment Limited Partnership Method for measuring blood procoagulant activity of human leukocyte antigens
AU681341B2 (en) * 1992-01-28 1997-08-28 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
CA2157379A1 (en) * 1993-03-02 1994-09-15 David S. Terman Method of cancer treatment
US5585465A (en) * 1993-04-05 1996-12-17 National Jewish Center For Immunology And Respiratory Medicine Isolated toxin associated with Kawasaki syndrome
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US6075119A (en) 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
WO2000020598A1 (en) * 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
CA3066053A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE91237T1 (de) * 1986-10-16 1993-07-15 Harvard College Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen.
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent

Also Published As

Publication number Publication date
DE69133068T2 (de) 2003-03-13
EP0511306B1 (de) 2002-07-17
EP1129717B2 (de) 2013-03-06
EP1103268B1 (de) 2005-08-31
CA2078003A1 (en) 1991-07-18
ATE303157T1 (de) 2005-09-15
EP0511306A1 (de) 1992-11-04
DE69133484T2 (de) 2006-05-18
DE69133068D1 (de) 2002-08-22
EP1129717B1 (de) 2005-09-14
ATE304371T1 (de) 2005-09-15
CA2078003C (en) 2006-11-21
WO1991010680A1 (en) 1991-07-25
DE69133484D1 (de) 2005-10-06
EP1129717A1 (de) 2001-09-05
DE69133485T2 (de) 2006-06-22
DE69133485D1 (de) 2005-10-20
EP0511306A4 (en) 1993-04-28
EP1103268A1 (de) 2001-05-30

Similar Documents

Publication Publication Date Title
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
NO893769D0 (no) Fremgangsmaate for behandling av naturgass.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
DK0538300T3 (da) O-Glycosyleret IFN-alfa
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DE69327534D1 (de) Impfstoffe gegen diphtherietoxin
DK1266965T3 (da) Rekombinante antistoffer til human terapi
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
SE9704546D0 (sv) Novel compounds
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DK0648503T3 (da) Pro-prodrugs, deres fremstilling og anvendelse
NO910340L (no) Topiske preparater for behandling av menneskenegler.
ATE150319T1 (de) Behandlung von asthma
DE69434384D1 (de) Metalkomplexbildner
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
NO973548L (no) Behandling av diabetisk neuropati
NO911429D0 (no) Stoffbehandling.
DE69907926D1 (de) 1,2,4-triazol-3-thion verbindungen
NO911430D0 (no) Stoffbehandlingsmetode.
ATE112168T1 (de) Menschlicher hitzeschock-faktor.
FI890864A0 (fi) Anvaendning av 1,4-dihydropyridinderivat.